Shankar Nagasri, Ramani Azaan, Griffin Connor, Agbim Uchenna, Kim Donghee, Ahmed Aijaz, Asrani Sumeet K
Baylor University Medical Center, Dallas, TX, USA.
The University of Tennessee Health Science Center, Saint Louis University, MO, USA.
Ann Hepatol. 2021 Dec;26:100565. doi: 10.1016/j.aohep.2021.100565. Epub 2021 Oct 30.
Cirrhosis-related mortality is underestimated and is increasing; extrahepatic factors may contribute. We examined trends in cirrhosis mortality from 1999-2017 in the United States attributed to liver-related (varices, peritonitis, hepatorenal syndrome, hepatic encephalopathy, hepatocellular carcinoma, sepsis) or extrahepatic (cardiovascular disease, influenza and pneumonia, diabetes, malignancy) causes, and compared mortality trends with congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) populations.
A national mortality database was used. Changes in age-standardized mortality over time were determined by joinpoint analysis. Average annual percentage change (AAPC) was estimated.
Cirrhosis cohort: From 1999-2017, both liver-related (AAPC 1.3%; 95% confidence interval [CI] 0.7-1.9) and extrahepatic mortality (AAPC 1.0%; 95% CI 0.7-1.2) increased. Cirrhosis vs other chronic disease cohorts: changes in all-cause mortality were higher in cirrhosis (AAPC 1.0%; 95% CI 0.7-1.4) than CHF (AAPC 0.1%; 95% CI -0.5- 0.8) or COPD (AAPC -0.4%; 95% CI -0.6- -0.2). Sepsis mortality was highest in cirrhosis (AAPC 3.6%, 95% 3.2- 4.1) compared to CHF (AAPC 0.6%, 95% CI -0.5- 1.7) or COPD (AAPC 0.8%, 95% CI 0.5- 1.2). Cardiovascular mortality increased in cirrhosis (AAPC 1.3%, 95% CI 1.1- 1.5), declined in CHF (AAPC -2.0%, 95% CI -5.3- 1.3) and remained unchanged in COPD (AAPC 0.1%, 95% CI -0.2- 0.4). Extrahepatic mortality was higher among women, rural populations, and individuals >65 years with cirrhosis.
Extrahepatic causes of death are important drivers of mortality and differentially impact cirrhosis compared to other chronic diseases.
肝硬化相关死亡率被低估且呈上升趋势;肝外因素可能起了作用。我们研究了1999年至2017年美国肝硬化死亡率的趋势,这些死亡归因于肝脏相关病因(静脉曲张、腹膜炎、肝肾综合征、肝性脑病、肝细胞癌、败血症)或肝外病因(心血管疾病、流感和肺炎、糖尿病、恶性肿瘤),并将死亡率趋势与充血性心力衰竭(CHF)和慢性阻塞性肺疾病(COPD)人群进行了比较。
使用了一个国家死亡率数据库。通过连接点分析确定年龄标准化死亡率随时间的变化。估计了平均年度百分比变化(AAPC)。
肝硬化队列:1999年至2017年,肝脏相关死亡率(AAPC 1.3%;95%置信区间[CI]0.7 - 1.9)和肝外死亡率(AAPC 1.0%;95% CI 0.7 - 1.2)均有所上升。肝硬化与其他慢性病队列比较:肝硬化的全因死亡率变化(AAPC 1.0%;95% CI 0.7 - 1.4)高于CHF(AAPC 0.1%;95% CI -0.5 - 0.8)或COPD(AAPC -0.4%;95% CI -0.6 - -0.2)。与CHF(AAPC 0.6%;95% CI -0.5 - 1.7)或COPD(AAPC 0.8%;95% CI 0.5 - 1.2)相比,肝硬化患者的败血症死亡率最高(AAPC 3.6%,95% 3.2 - 4.1)。肝硬化患者的心血管死亡率上升(AAPC 1.3%;95% CI 1.1 - 1.5),CHF患者的心血管死亡率下降(AAPC -2.0%;95% CI -5.3 - 1.3),COPD患者的心血管死亡率保持不变(AAPC 0.1%;95% CI -0.2 - 0.4)。肝硬化女性、农村人群以及年龄>65岁的肝硬化患者的肝外死亡率更高。
肝外死因是死亡率的重要驱动因素,与其他慢性病相比,对肝硬化死亡率的影响存在差异。